RU2688675C2 - Соединения хинона и их применения для лечения рака - Google Patents

Соединения хинона и их применения для лечения рака Download PDF

Info

Publication number
RU2688675C2
RU2688675C2 RU2015105036A RU2015105036A RU2688675C2 RU 2688675 C2 RU2688675 C2 RU 2688675C2 RU 2015105036 A RU2015105036 A RU 2015105036A RU 2015105036 A RU2015105036 A RU 2015105036A RU 2688675 C2 RU2688675 C2 RU 2688675C2
Authority
RU
Russia
Prior art keywords
cancer
diaphorase
compound
treating
treating cancer
Prior art date
Application number
RU2015105036A
Other languages
English (en)
Russian (ru)
Other versions
RU2015105036A (ru
Inventor
Алан МАКГАУН
Джон ХЭДФИЛД
Джон БАТЛЕР
Original Assignee
ОНКО-ЭнЭкс ЛИМИТЕД
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ОНКО-ЭнЭкс ЛИМИТЕД filed Critical ОНКО-ЭнЭкс ЛИМИТЕД
Publication of RU2015105036A publication Critical patent/RU2015105036A/ru
Application granted granted Critical
Publication of RU2688675C2 publication Critical patent/RU2688675C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D203/08—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
    • C07D203/14—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom with carbocyclic rings directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2015105036A 2012-07-30 2013-07-30 Соединения хинона и их применения для лечения рака RU2688675C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1213486.2A GB201213486D0 (en) 2012-07-30 2012-07-30 Quinone compounds and their uses for the treatment of cancer
GB1213486.2 2012-07-30
PCT/EP2013/065968 WO2014020012A1 (en) 2012-07-30 2013-07-30 Quinone compounds and their uses for the treatment of cancer

Publications (2)

Publication Number Publication Date
RU2015105036A RU2015105036A (ru) 2016-09-20
RU2688675C2 true RU2688675C2 (ru) 2019-05-22

Family

ID=46881339

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015105036A RU2688675C2 (ru) 2012-07-30 2013-07-30 Соединения хинона и их применения для лечения рака

Country Status (16)

Country Link
US (1) US9266829B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2882743B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP6317742B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR102142164B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN104583200B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2013298653B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112015001837B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2880021C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK2882743T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2662917T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (2) GB201213486D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2015DN01223A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX361650B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO2882743T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2688675C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2014020012A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115887684B (zh) * 2022-12-02 2025-02-14 南京邮电大学 基于dna折纸和阿霉素前药构筑的递药纳米体系及方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156744A (en) * 1998-03-19 2000-12-05 Cancer Research Campaign Tech (London) DT-diaphorase directed anti-tumor agents
RU2009137770A (ru) * 2007-03-13 2011-04-20 Спектрум Фармасьютикалз, Инк. (Us) Внутрипузырное введение апазиквона после трансуретральной резекции при лечении рака

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008503579A (ja) * 2004-06-21 2008-02-07 ハッチソン メディファーマ エンタープライジズ リミテッド 癌の化学療法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156744A (en) * 1998-03-19 2000-12-05 Cancer Research Campaign Tech (London) DT-diaphorase directed anti-tumor agents
RU2009137770A (ru) * 2007-03-13 2011-04-20 Спектрум Фармасьютикалз, Инк. (Us) Внутрипузырное введение апазиквона после трансуретральной резекции при лечении рака

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HIDEO NAKAO ET AL. "Antileukemic agents. II. new 2,5-bis(1-aziridinyl)-p-benzoquinone derivatives", CHEMICAL AND PHARMACEUTICAL BULLETIN, 1972, vol. 20, no. 9, pages 1968-1979. *
KHAN P ET AL. "Development and validation of a sensitive solid-phase extraction and high-performance liquid chromatographic assay for the novel bio-reductive anti-tumor agent RH1 in human and mouse plasma", JOURNAL OF CHROMATOGRAPHY B : BIOMEDICAL APPLICATIONS, 1999, vol. 729, no. 1-2, pages 287-295. *
KHAN P ET AL. "Development and validation of a sensitive solid-phase extraction and high-performance liquid chromatographic assay for the novel bio-reductive anti-tumor agent RH1 in human and mouse plasma", JOURNAL OF CHROMATOGRAPHY B : BIOMEDICAL APPLICATIONS, 1999, vol. 729, no. 1-2, pages 287-295. HIDEO NAKAO ET AL. "Antileukemic agents. II. new 2,5-bis(1-aziridinyl)-p-benzoquinone derivatives", CHEMICAL AND PHARMACEUTICAL BULLETIN, 1972, vol. 20, no. 9, pages 1968-1979. YOSHIMOTO, MASAFUMI ET AL. "Quantitative structure-activity relationships in 2,5-bis(1-aziridinyl)-p-benzoquinone derivatives against leukemia l-1210", JOURNAL OF MEDICINAL CHEMISTRY, 1979, vol. 22, no. 5, pages 491-496. *
YOSHIMOTO, MASAFUMI ET AL. "Quantitative structure-activity relationships in 2,5-bis(1-aziridinyl)-p-benzoquinone derivatives against leukemia l-1210", JOURNAL OF MEDICINAL CHEMISTRY, 1979, vol. 22, no. 5, pages 491-496. *

Also Published As

Publication number Publication date
KR20150036215A (ko) 2015-04-07
GB2519004A (en) 2015-04-08
CN104583200A (zh) 2015-04-29
AU2013298653B2 (en) 2017-10-19
HK1209111A1 (zh) 2016-03-24
IN2015DN01223A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-06-26
CN104583200B (zh) 2017-07-25
AU2013298653A1 (en) 2015-02-19
NO2882743T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2018-05-12
GB2519004B (en) 2016-03-30
MX2015000969A (es) 2015-09-23
CA2880021C (en) 2020-01-14
US20150210639A1 (en) 2015-07-30
EP2882743B1 (en) 2017-12-13
EP2882743A1 (en) 2015-06-17
BR112015001837B1 (pt) 2021-11-16
US9266829B2 (en) 2016-02-23
BR112015001837A2 (pt) 2017-07-04
MX361650B (es) 2018-12-13
CA2880021A1 (en) 2014-02-06
JP2015524815A (ja) 2015-08-27
DK2882743T3 (en) 2018-03-12
WO2014020012A1 (en) 2014-02-06
KR102142164B1 (ko) 2020-08-06
RU2015105036A (ru) 2016-09-20
ES2662917T3 (es) 2018-04-10
GB201213486D0 (en) 2012-09-12
JP6317742B2 (ja) 2018-04-25

Similar Documents

Publication Publication Date Title
US10201516B2 (en) Targeting K-Ras-mediated signaling pathways and malignancy by prostratin
Yelton et al. Histone deacetylase enzymes and selective histone deacetylase inhibitors for antitumor effects and enhancement of antitumor immunity in glioblastoma
JP2010540555A (ja) アザシチジン類似体およびその使用
Liu et al. LSD1 in drug discovery: From biological function to clinical application
EP4219488A1 (en) Method for the preparation of urea compounds as smarca2/brm-atpase inhibitors
CN112672789A (zh) 用于治疗癌症的5-乙酰氨基甲基-噁唑烷酮衍生物
RU2688675C2 (ru) Соединения хинона и их применения для лечения рака
CN111867587A (zh) 用于治疗癌症的硫氧还蛋白还原酶抑制剂
WO2021094827A1 (en) Use of bisantrene to treat measurable residual disease in acute myeloid leukemia
WO2014006625A1 (en) Pharmaceutical composition comprising amino-phenyl- acetic acid octadec-(z)-9-enyl ester and use thereof for treating tumors
EP4495238A2 (en) Targeting egln1 in cancer
JP7541512B2 (ja) プロドラッグおよびその医学的使用
EP4520399A2 (en) Organic compounds
US20230181564A1 (en) Potent Tetrahydroquinolone Eliminates Apicomplexan Parasites
CN111448181A (zh) 单脒和二脒核酸内切-外切酶抑制剂和抑制核酸内切-外切酶活性的方法
US20240190817A1 (en) Methods of treating cancer
EP4035666A1 (en) Aminothiolester compound or derivative thereof for use as an immunomodulatory agent
WO2025137355A1 (en) Proxy binding for screening therapeutic compounds
Morenikeji Increasing the Efficacy of Actinomycin D With Resveratrol in Aerodigestive Tract Cancers
Raji Increasing the efficacy of Actinomycin D with Resveratrol in Aerodigestive tract cancers
WO2022094477A1 (en) Methods of treating tumors and cancers having dysregulated wnt signaling pathways
HK40045602B (en) Urea compounds and compositions as smarca2/brm-atpase inhibitors
HK40045602A (en) Urea compounds and compositions as smarca2/brm-atpase inhibitors
Zhou et al. The role of the HGF/c-Met signaling pathway in crizotinib-induced apoptosis in lung cancer with c-Met amplification⁎

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20200731